explore -WSS

explore

author：focus 2025-10-02 22:27:13 - browse：622

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Congenital heart disease patients face new threat of heart failure

entertainment

WSS

Patient advocates debate FDA's accelerated approval process

The woman behind the Dana Farber

FDA needs staff influx to meet gene therapy needs, Marks says

What PEPFAR has meant on the ground in Ukraine

Radiology is caught between AI's potential and concern for patients

After sickle

knowledge

explore

entertainment

Medical leaders decry Supreme Court decision on affirmative action

STAT letters to the editor on burnt

Hepatitis C has a cure — but many Americans still lack access to it

Steward Health Care has deal to sell doctor network to UnitedHealth

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

23andMe had bad news about my health. I wish a person had delivered it

Leukemia patients are helped by Syndax's new type of therapy

Medical records are filled with copy

FDA's naming rule on biosimilars has undermined competition

entertainment

Patients' immediate access to test results puts radiologists in a bind

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Supreme Court mifepristone arguments center on docs' right to sue

Pharma patents targeted by Biden in move to slash drug prices

Patients' immediate access to test results puts radiologists in a bind

Teach medical students about patients with intellectual disabilities

hotspot

knowledge

entertainment

leisure time